Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04249232 · ClinicalTrials.gov registry record · Phase 2
Abaloparatide and Pelvic Fracture Healing
A Phase 2 study of Fracture of Pelvis (Disorder), sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 3
- Study locations
NCT04249232 is a Phase 2 study of Fracture of Pelvis (Disorder) that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 48 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT04249232, a Phase 2 study of Fracture of Pelvis (Disorder), has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a prospective randomized, double-blinded, placebo-controlled, phase 2, three-month study of the efficacy of abaloparatide in postmenopausal women and men ≥ 50 years of age with acute fractures of the pelvis (n=78). The primary outcome is CT image based evidence of fracture healing. The secondary aims are pain and physical performance measures at 3 months. This study will be extended with 9 months of open label abaloparatide to determine if any potential differences between the placebo and abaloparatide groups during the 3 months of treatment are evident and persist over time, even in patients who use abaloparatide after the three-month placebo controlled intervention.
Conditions Studied
Interventions
- DRUG Abaloparatide 80 micrograms per Pen dose
- DRUG Placebo prefilled injector pen
Study Locations (3)
New York
- Hospital for Special Surgery - New York
- Mount Sinai - New York
- Westchester Medical Center - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2024-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04249232
The ClinicalTrials.gov registry entry for NCT04249232 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fracture of Pelvis (Disorder) appearing as the primary indexed condition, and to 2 interventions - of which Abaloparatide 80 micrograms per Pen dose is the first listed.
NCT04249232 reports 3 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04249232 about?
NCT04249232 is a clinical study titled "Abaloparatide and Pelvic Fracture Healing". This is a prospective randomized, double-blinded, placebo-controlled, phase 2, three-month study of the efficacy of abaloparatide in postmenopausal women and men ≥ 50 years of age with acute fractures of the pelvis (n=78). The primary outcome is CT image based evidence of fracture healing. The secon...
What is the current status of trial NCT04249232?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-09-17. Estimated completion is 2024-04-25.
What conditions does trial NCT04249232 study?
This clinical trial studies the following conditions: Fracture of Pelvis (Disorder).
What interventions are being tested in trial NCT04249232?
The interventions under investigation include: Abaloparatide 80 micrograms per Pen dose (DRUG), Placebo prefilled injector pen (DRUG).
Who is sponsoring clinical trial NCT04249232?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04249232 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.